COCKTAILS OF RICIN A-CHAIN IMMUNOTOXINS AGAINST DIFFERENT ANTIGENS ON HODGKIN AND STERNBERG-REED CELLS HAVE SUPERIOR ANTITUMOR EFFECTS AGAINST H-RS CELLS IN-VITRO AND SOLID HODGKIN TUMORS IN MICE

被引:26
作者
ENGERT, A [1 ]
GOTTSTEIN, C [1 ]
BOHLEN, H [1 ]
WINKLER, U [1 ]
SCHON, G [1 ]
MANSKE, O [1 ]
SCHNELL, R [1 ]
DIEHL, V [1 ]
THORPE, P [1 ]
机构
[1] UNIV TEXAS, SW MED CTR, HAROLD C SIMMONS COMPREHENS CANC CTR, DALLAS, TX USA
关键词
D O I
10.1002/ijc.2910630226
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Three ricin A-chain immunotoxins (ITs) recognizing different antigens on Hodgkin-Reed/Sternberg (H-RS) cells were evaluated for their anti-tumor effects when used in combination as ''cocktails'', These ITs, BB10.dgA (CD25), HRS3.dgA (CD30), and IRac.dgA (70 kDa), strongly inhibited the growth of L540Cy H-RS cells in vitro. The protein synthesis of this cell line was reduced more efficiently by the combination of 2 of these ITs than by BB10.dgA, HRS3.dgA or IRac.dgA alone. A cocktail of all 3 ITs was most effective in vitro. This was at least in part due to the non-homogeneous distribution of CD25, CD30 or IRac on the L540Cy H-RS target cells and to the fact that subpopulations deficient in one antigen nevertheless expressed appreciable levels of the other target antigens. IT cocktails were also superior as anti-tumor agents in nude mice with solid L540Cy tumors. Ninety percent of mice treated with cocktails containing 2 or 3 ITs had continuous complete remissions (CCR), as compared with only 40% of mice treated with the same dose of a single IT. Analysis of 7 L540Cy sub-lines re-established ex vivo from mice that relapsed after having achieved complete remission (CR) after therapy with a single IT showed that the surviving tumor cells were antigen-deficient variants which were resistant to the original IT, but which could be killed by ITs directed against other target antigens. Thus, IT cocktails give superior results against human H-RS cells, both in vitro and in vivo. (C) 1995 Wiley-Liss, Inc.
引用
收藏
页码:304 / 309
页数:6
相关论文
共 28 条
[1]  
AMLOT PL, 1993, BLOOD, V82, P2624
[2]  
BERENBECK C, 1989, LEUKOCYTE TYPING, V4, P419
[3]  
DIEHL V, 1982, CANCER TREAT REP, V66, P615
[4]  
ENGERT A, 1990, CANCER RES, V50, P84
[5]   IMMUNOTOXINS CONSTRUCTED WITH ANTI-CD25 MONOCLONAL-ANTIBODIES AND DEGLYCOSYLATED RICIN A-CHAIN HAVE POTENT ANTITUMOR EFFECTS AGAINST HUMAN HODGKIN CELLS-INVITRO AND SOLID HODGKIN TUMORS IN MICE [J].
ENGERT, A ;
MARTIN, G ;
AMLOT, P ;
WIJDENES, J ;
DIEHL, V ;
THORPE, P .
INTERNATIONAL JOURNAL OF CANCER, 1991, 49 (03) :450-456
[6]  
ENGERT A, 1990, CANCER RES, V50, P2929
[7]  
ENGERT A, 1994, BLOOD S, V84, pA2549
[8]   RESPONSE OF REFRACTORY HODGKINS-DISEASE TO MONOCLONAL ANTI-CD30 IMMUNOTOXIN [J].
FALINI, B ;
BOLOGNESI, A ;
FLENGHI, L ;
TAZZARI, PL ;
BROE, MK ;
STEIN, H ;
DURKOP, H ;
AVERSA, F ;
CORNELI, P ;
PIZZOLO, G ;
BARBABIETOLA, G ;
SABATTINI, E ;
PILERI, S ;
MARTELLI, MF ;
STIRPE, F .
LANCET, 1992, 339 (8803) :1195-1196
[9]  
GHETIE MA, 1992, BLOOD, V80, P2315
[10]   ANTI-B4-BLOCKED RICIN - A PHASE-I TRIAL OF 7-DAY CONTINUOUS INFUSION IN PATIENTS WITH B-CELL NEOPLASMS [J].
GROSSBARD, ML ;
LAMBERT, JM ;
GOLDMACHER, VS ;
SPECTOR, NL ;
KINSELLA, J ;
ELISEO, L ;
CORAL, F ;
TAYLOR, JA ;
BLATTLER, WA ;
EPSTEIN, CL ;
NADLER, LM .
JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (04) :726-737